Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

Launched by ELGAN PHARMA LTD. · Jan 2, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ELGN-2112 to see how well it helps preterm infants who have a condition called intestinal malabsorption, which means their bodies have trouble absorbing nutrients from food. The trial will focus on infants who were born between 26 and 32 weeks of pregnancy and weigh at least 500 grams. This means that both boys and girls who fit these criteria may be eligible to participate.

If your child is selected for this study, they will be closely monitored while receiving the treatment to assess its safety and effectiveness. The trial is still in the planning stages and has not yet started recruiting participants, but it aims to improve the health of preterm infants struggling with this condition. If you have any further questions about the trial or your child's eligibility, please reach out to the research team when it becomes available.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female pre-term infant 26 and up to 32 weeks gestation. Gestational age matching (±2 weeks) between maternal dates and/or early antenatal ultrasound
• • Birth weight ≥ 500g
• • Singleton or twin birth
• Exclusion Criteria:
• • -